Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures: 2014-2024

Historic Capital Expenditures for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $9.1 million.

  • Cartesian Therapeutics' Capital Expenditures fell 76.55% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 32.95%. This contributed to the annual value of $9.1 million for FY2024, which is 4314.08% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Capital Expenditures is $9.1 million, which was up 4,314.08% from $206,000 recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Capital Expenditures registered a high of $9.1 million during FY2024, and its lowest value of $206,000 during FY2023.
  • In the last 3 years, Cartesian Therapeutics' Capital Expenditures had a median value of $1.2 million in 2022 and averaged $3.5 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Capital Expenditures slumped by 82.85% in 2023, and later skyrocketed by 4,314.08% in 2024.
  • Cartesian Therapeutics' Capital Expenditures (Yearly) stood at $815,000 in 2020, then spiked by 33.13% to $1.1 million in 2021, then rose by 10.69% to $1.2 million in 2022, then slumped by 82.85% to $206,000 in 2023, then surged by 4,314.08% to $9.1 million in 2024.